Literature DB >> 16402354

The Cys allele of the DRD2 Ser311Cys polymorphism has a dominant effect on risk for schizophrenia: evidence from fixed- and random-effects meta-analyses.

Stephen J Glatt1, Erik G Jönsson.   

Abstract

Previously we derived independent estimates of the effect of the dopamine D2 receptor (DRD2) Ser311Cys polymorphism on risk for schizophrenia using fixed- and random-effects meta-analyses. Both analyses identified a significant association between the Cys allele and schizophrenia, but neither included all available data. Furthermore, genotype data were not evaluated in either analysis, thus precluding any determination of the mode of inheritance. The present study was conducted to resolve discrepancies between the existing meta-analyses, and provide more comprehensive and accurate estimates of the nature and magnitude of the influence of the Ser311Cys polymorphism on risk for schizophrenia. All discrepancies between the two sets of previously meta-analyzed studies were identified and resolved to the mutual satisfaction of the authors, and the final dataset was analyzed independently by fixed- and random-effects meta-analyses. A total of 27 samples, comprising 3,707 schizophrenia patients and 5,363 control subjects, were included in the analyses of allelic association, while smaller numbers of studies and subjects were included in each of the genotypic association analyses. A significant effect of the Cys allele was observed under both fixed-effects (odds ratio [OR] = 1.4; P = 0.002) and random-effects (OR = 1.4; P = 0.007) models. Cys/Ser heterozygotes were at elevated risk for schizophrenia when compared to Ser/Ser homozygotes (fixed- and random-effects OR = 1.4, p(s) <or= 0.005), but Cys/Cys homozygotes were at no elevated risk relative to heterozygotes (OR = 1.0, p(s) >or= 0.948). There was no evidence of heterogeneity, excessive influence of any single study, or publication bias in any of the analyses, suggesting that the effect of this DRD2 polymorphism on schizophrenia risk is reliable and uniform across populations, and our estimates of its magnitude are robust and accurate. (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16402354      PMCID: PMC2568898          DOI: 10.1002/ajmg.b.30273

Source DB:  PubMed          Journal:  Am J Med Genet B Neuropsychiatr Genet        ISSN: 1552-4841            Impact factor:   3.568


  34 in total

1.  Polymorphism of dopamine receptors and transporter genes in neuropsychiatric diseases.

Authors:  Y Fujiwara; K Yamaguchi; Y Tanaka; H Tomita; Y Shiro; K Kashihara; K Sato; S Kuroda
Journal:  Eur Neurol       Date:  1997       Impact factor: 1.710

2.  Linkage and association of a functional DRD2 variant [Ser311Cys] and DRD2 markers to alcoholism, substance abuse and schizophrenia in Southwestern American Indians.

Authors:  D Goldman; M Urbanek; D Guenther; R Robin; J C Long
Journal:  Am J Med Genet       Date:  1997-07-25

3.  Bias in meta-analysis detected by a simple, graphical test.

Authors:  M Egger; G Davey Smith; M Schneider; C Minder
Journal:  BMJ       Date:  1997-09-13

4.  An association study between the Cys311 variant of dopamine D2 receptor gene and schizophrenia in the Okinawan population.

Authors:  M Kaneshima; T Higa; H Nakamoto; M Nagamine
Journal:  Psychiatry Clin Neurosci       Date:  1997-12       Impact factor: 5.188

5.  Dopamine receptor D2 Ser/Cys 311 variant is associated with delusion and disorganization symptomatology in major psychoses.

Authors:  A Serretti; E Lattuada; C Lorenzi; R Lilli; E Smeraldi
Journal:  Mol Psychiatry       Date:  2000-05       Impact factor: 15.992

6.  The influence on the schizophrenic symptoms by the DRD2Ser/Cys311 and -141C Ins/Del polymorphisms.

Authors:  Akio Himei; Jun Koh; Jun Sakai; Yasushi Inada; Kazuyo Akabame; Hiroshi Yoneda
Journal:  Psychiatry Clin Neurosci       Date:  2002-02       Impact factor: 5.188

7.  Ser-311-Cys polymorphism of the dopamine D2 receptor gene and schizophrenia--an analysis of schizophrenic patients in Fukuoka.

Authors:  M Harano
Journal:  Kurume Med J       Date:  1997

Review 8.  Atypical antipsychotics: mechanism of action.

Authors:  Philip Seeman
Journal:  Can J Psychiatry       Date:  2002-02       Impact factor: 4.356

9.  European Multicentre Association Study of Schizophrenia: a study of the DRD2 Ser311Cys and DRD3 Ser9Gly polymorphisms.

Authors:  G Spurlock; J Williams; P McGuffin; H N Aschauer; E Lenzinger; K Fuchs; W C Sieghart; K Meszaros; N Fathi; C Laurent; J Mallet; F Macciardi; S Pedrini; M Gill; Z Hawi; S Gibson; E E Jazin; H T Yang; R Adolfsson; C N Pato; A M Dourado; M J Owen
Journal:  Am J Med Genet       Date:  1998-02-07

10.  Meta-analysis in psychiatric genetics.

Authors:  Douglas F Levinson
Journal:  Curr Psychiatry Rep       Date:  2005-04       Impact factor: 8.081

View more
  20 in total

1.  PharmGKB summary: dopamine receptor D2.

Authors:  Huaiyu Mi; Paul D Thomas; Huijun Z Ring; Ruhong Jiang; Katrin Sangkuhl; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2011-06       Impact factor: 2.089

Review 2.  The neuregulin signaling pathway and schizophrenia: from genes to synapses and neural circuits.

Authors:  Andrés Buonanno
Journal:  Brain Res Bull       Date:  2010-08-03       Impact factor: 4.077

3.  Identification of genetic loci underlying the phenotypic constructs of autism spectrum disorders.

Authors:  Xiao-Qing Liu; Stelios Georgiades; Eric Duku; Ann Thompson; Bernie Devlin; Edwin H Cook; Ellen M Wijsman; Andrew D Paterson; Peter Szatmari
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2011-07       Impact factor: 8.829

4.  Alternatively Spliced Genes as Biomarkers for Schizophrenia, Bipolar Disorder and Psychosis: A Blood-Based Spliceome-Profiling Exploratory Study.

Authors:  S J Glatt; S D Chandler; C A Bousman; G Chana; G R Lucero; E Tatro; T May; J B Lohr; W S Kremen; I P Everall; M T Tsuang
Journal:  Curr Pharmacogenomics Person Med       Date:  2009-09

5.  Similarities and differences in peripheral blood gene-expression signatures of individuals with schizophrenia and their first-degree biological relatives.

Authors:  Stephen J Glatt; William S Stone; Nadine Nossova; Choong-Chin Liew; Larry J Seidman; Ming T Tsuang
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2011-10-03       Impact factor: 3.568

Review 6.  G protein-coupled receptors in major psychiatric disorders.

Authors:  Lisa A Catapano; Husseini K Manji
Journal:  Biochim Biophys Acta       Date:  2006-10-03

7.  Family-based association testing strongly implicates DRD2 as a risk gene for schizophrenia in Han Chinese from Taiwan.

Authors:  S J Glatt; S V Faraone; J A Lasky-Su; T Kanazawa; H-G Hwu; M T Tsuang
Journal:  Mol Psychiatry       Date:  2008-03-11       Impact factor: 15.992

8.  Genetic associations with schizophrenia: meta-analyses of 12 candidate genes.

Authors:  Jiajun Shi; Elliot S Gershon; Chunyu Liu
Journal:  Schizophr Res       Date:  2008-08-20       Impact factor: 4.939

Review 9.  Dopamine genes and schizophrenia: case closed or evidence pending?

Authors:  Michael E Talkowski; Mikhil Bamne; Hader Mansour; Vishwajit L Nimgaonkar
Journal:  Schizophr Bull       Date:  2007-07-14       Impact factor: 9.306

10.  Comparative sequence and structural analyses of G-protein-coupled receptor crystal structures and implications for molecular models.

Authors:  Catherine L Worth; Gunnar Kleinau; Gerd Krause
Journal:  PLoS One       Date:  2009-09-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.